<DOC>
	<DOCNO>NCT01473888</DOCNO>
	<brief_summary>Purpose : This study determine effect T89 ( Dantonic® ) P450 enzymes . This study help determine type drug may interact T89 .</brief_summary>
	<brief_title>A Study To Evaluate The Effect T89 ( Dantonic® ) On P450 Enzymes</brief_title>
	<detailed_description>T89 modernize industrialized version traditional Chinese herbal medicine . T89 approve market drug , treatment chronic stable angina pectoris due coronary heart disease , State Food Drug Administration ( SFDA ) China 1993 . There 2 billion dos prescribe use , 10,000,000 subject , short long-term administration worldwide . The product also market , drug , Russia , South Korea , Mongolia , Singapore , Vietnam , South Africa . The current study determine anti-angina effect dose response T89 patient chronic stable angina pectoris United States . T89 consist Danshen ( Radix Salviae Miltiorrhizae , RSM ) Sanqi ( Radix Notoginseng , RN ) active constitutes , use Borneol transport enhancer .</detailed_description>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>Nonsmoking Male female 1850 year age , body mass index ( BMI ) 18 ≤ 30 kg/m2 Healthy adult active medical problem significant chronic disease determine study doctor base history , physical exam laboratory evaluation ; Avoid eat Seville orange , grapefruit ( include grapefruit juice ) , broccoli , brussels sprout , charcoalgrilled meat , alcoholic beverage , caffeine theobrominecontaining beverage foods duration study begin screen visit . Females child bear potential must able maintain adequate birth control study ; define double barrier method complete abstinence . Females nonchild bear potential must provide documentation tubal ligation hysterectomy . Be able provide write informed consent comply requirement study ; Be able read , speak understand English Clinically significant abnormal finding history , physical exam , ECG , laboratory testing determine study doctor . Know hypersensitivity intolerance probe substrates active and/or inactive ingredient probe substrate , flumazenil , guaifenesin , vitamin K ; A history illicit drug use history alcohol abuse within 1 year screening . Women pregnant , breastfeeding , and/or use acceptable form nonhormonal contraception ( double barrier method abstinence ) study . History gastrointestinal bleeding peptic ulcer disease . Any condition may affect drug absorption ( e.g. , gastrectomy , malabsorption syndrome ) . Had elevate international normalize ratio ( INR ) time ( INR &gt; 1.2 ) screening Day1 . Had take nicotinecontaining nicotine replacement device within 6 month screen visit Had take prescription drug 3 month screen visit Had take nonprescription drug ( include natural health product , Vitamins , herbal ) period 7 day prior screen visit Had receive immunization 2 week prior screen visit Had know immune deficiency disease positive human immunodeficiency virus , Hepatitis B Hepatitis C virus . Use drug know inhibit induce hepatic enzyme within 30 day first study phase . Regular alcohol intake exceed 1 drink/day ( 1 drink = 5 ounce wine 12 ounce beer 1 ounce hard liquor ) within 7 day screen . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study drug . Presence condition investigator feel would interfere successful completion study . Genotyping poor metabolizers CYP2D6 , CYP2C9 , CYP2C19 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>T89 ( Dantonic® )</keyword>
	<keyword>Cooperstown 5+1 cocktail probe</keyword>
	<keyword>CYP450</keyword>
</DOC>